3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Phase 2/3
1
Status
Recruiting
3
Unknown
1
Terminated
1
Completed
1
Sponsor Class
OTHER
3
Study Type
Interventional
2
Observational
1
Sponsor
Cancer Type
NET
3
Endocrine
3
Gastrointestinal
1
Conditions
Neuroendocrine Tumors
3
Rectal Neoplasms
1
Gastro-enteropancreatic neuroendocrine tumor
1
Carcinoma, Neuroendocrine
1
Anastomotic Leak
1
Interventions
lutetium Lu 177 dotatate
10
Everolimus
5
lanreotide
4
gallium Ga 68 dotatate
4
Nivolumab
4
Magnetic Resonance Spectroscopy
4
177Lu-octreotide, DOTA(0)-Tyr(3)-
4
olaparib
3
Temozolomide
3
Somatostatin
3
Capecitabine
3
surufatinib
2
pembrolizumab
2
copper dotatate CU-64
2
cabozantinib
2
amino-acid, glucose, and electrolyte solution
2
Specimen Handling
2
Octreotide
2
Lutetium-177
2
Lutetium
2
Injections
2
Fluorodeoxyglucose F18
2
Cyclophosphamide
2
tivozanib
1
talazoparib
1
sintilimab
1
repotrectinib
1
lenvatinib
1
guarana powder
1
gadoteridol
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Recruiting
×
Neuroendocrine Tumors
×
Somatostatin
×
Clear all
NCT04464122
2025-04-03
REBORN
University of Roma La Sapienza
Recruiting
60 enrolled
NCT06855095
2025-03-03
ATSA
The Netherlands Cancer Institute
Phase 2/3
Recruiting
39 enrolled
NCT05701241
2024-06-14
SAUNA
University Hospital, Antwerp
Phase 4
Recruiting
270 enrolled